News und Analysen

Eric Sherbet, an executive at IQVIA Holdings Inc. (NYSE:IQV), sold 5,000 shares of common stock on July 29, 2026, according to a recent SEC Form 4 filing.

Transaction value based on SEC Form 4

Chairman and CEO Ari Bousbib reported a sale of about 106,000 shares of IQVIA Holdings Inc. (NYSE:IQV) for total proceeds of $26.1 million in an SEC Form 4 filing.

Transaction value based on SEC

Deciding between Advanced Micro Devices (NASDAQ:AMD) and Arm (NASDAQ:ARM) requires understanding their roles in the hardware ecosystem. One builds the chips, while the other provides the blueprint

Choosing between Abbott Laboratories (NYSE:ABT) and Eli Lilly (NYSE:LLY) involves weighing the steady diversification of a healthcare conglomerate against the high-velocity expansion of a

Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, reached a record high of $116.06 on Jan. 22. But today, the cancer test developer's stock trades at just under $70. Is

High-flying pharmaceutical company AbbVie (NYSE: ABBV) has seen its stock rise in many recent sessions. Yet Friday's wasn't one of them, as the company's shares took a nearly 3% loss on the back of

Shares of CareDx (NASDAQ: CDNA) climbed on Friday after the precision medicine diagnostics specialist lifted its full-year sales and earnings forecast.

Image source: Getty Images.

CareDx's revenue

Choosing between Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ) involves weighing steady growth against massive scale. Both healthcare giants offer stability, but which represents

At first glance, Pfizer (NYSE: PFE) looks like a great stock to buy. The company has a reliable dividend program and regularly raises its payouts, boasting a 6.8% forward yield, well above the S&P

President Donald Trump has not stopped using tariffs. In February, the Supreme Court ruled that the president's previous attempt at emergency-powers tariffs was unconstitutional. Now Trump is trying

This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals' acquisition of Crinetics

AT&T (NYSE: T) recently announced it's expanding its use of D-Wave Quantum (NASDAQ: QBTS) technology, just months after it began testing the quantum computing company's services.

AT&T said the

One of these enterprises was Biogen (NASDAQ: BIIB), which did quite well in its second quarter. As a reward, investors snapped up the stock, sending it to a nearly 2% gain on the day. This beat the

Shares of Revolution Medicines (NASDAQ: RVMD), a clinical-stage drugmaker, have gained 132% this year, easily outpacing the returns of leading pharmaceutical companies such as Eli Lilly (NYSE: LLY)

The first GLP-1 medicine was approved in the U.S. in 2005 for the treatment of type 2 diabetes. Since then, breakthroughs have occurred in the field. Medicines in this class are now indicated for

Dividend investing is a proven way to earn superior returns over long periods. That's because companies that can consistently pay -- and raise -- dividends tend to have strong underlying businesses

AbbVie (NYSE: ABBV), one of the world's largest pharmaceutical companies, is usually considered a blue chip dividend stock rather than a higher-growth one. Yet over the past five years, its stock

Medtronic (NYSE: MDT), one of the world's largest medical device makers, was once a reliable blue chip dividend stock. But over the past five years, its stock has declined 33%. Even after including